Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia

British Journal of Haematology

Volumn 145, Issue 4, 2009, Pages 441-454

  Fulda, Simone ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Bcl 2; Childhood leukaemia; Inhibitor of apoptosis proteins; Tumour necrosis factor related apoptosis inducing ligand

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; AEG 35156; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; DEATH RECEPTOR; FENRETINIDE; FLAVOPIRIDOL; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; LY 2813008; OBATOCLAX; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2; ROSCOVITINE; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MECHANISM; HUMAN; LYMPHOMA; MOLECULE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CHILD; DRUG RESISTANCE, NEOPLASM; GENES, BCL-2; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 65449161842     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07603.x     Document Type: Review

References (173)

1. Adams, J.M. Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26, 1324 1337. (Pubitemid 46328466)
2. Addeo, R., Caraglia, M., Baldi, A., D'Angelo, V., Casale, F., Crisci, S., Abbruzzese, A., Vincenze, B., Campioni, M., Di Tullio, M.T. Indolfi, P. (2005) Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL). Cancer Biology and Therapy, 4, 32 38. (Pubitemid 41350927)
3. Altieri, D.C. (2008) Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer, 8, 61 70.
4. Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., Pui, C.H. Masera, G. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine, 342, 998 1006. (Pubitemid 30180646)
5. Arnt, C.R., Chiorean, M.V., Heldebrant, M.P., Gores, G.J. Kaufmann, S.H. (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. Journal of Biological Chemistry, 277, 44236 44243. (Pubitemid 36157856)
6. Ashkenazi, A. (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine and Growth Factor Reviews, 19, 325 331.
7. Ashkenazi, A. Herbst, R.S. (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. Journal of Clinical Investigation, 118, 1979 1990.
8. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., DeForge, L., Koumenis, I.L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. Schwall, R.H. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation, 104, 155 162.
9. Ashkenazi, A., Holland, P. Eckhardt, S.G. (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of Clinical Oncology, 26, 3621 3630.
10. Bachmann, P.S., Gorman, R., Mackenzie, K.L., Lutze-Mann, L. Lock, R.B. (2005) Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood, 105, 2519 2526. (Pubitemid 40387054)
11. Belka, C., Schmid, B., Marini, P., Durand, E., Rudner, J., Faltin, H., Bamberg, M., Schulze-Osthoff, K. Budach, W. (2001) Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene, 20, 2190 2196. (Pubitemid 32424014)
12. Beltinger, C., Kurz, E., Bohler, T., Schrappe, M., Ludwig, W.D. Debatin, K.M. (1998a) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood, 91, 3943 3951. (Pubitemid 28225764)
13. Beltinger, C., Bohler, T., Karawajew, L., Ludwig, W.D., Schrappe, M. Debatin, K.M. (1998b) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 102, 722 728. (Pubitemid 28387055)
14. Bergmann, A., Agapite, J. Steller, H. (1998) Mechanisms and control of programmed cell death in invertebrates. Oncogene, 17, 3215 3223. (Pubitemid 29043974)
15. Bernardi, R. Pandolfi, P.P. (2003) Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene, 22, 9048 9057. (Pubitemid 38121705)
16. Birkey Reffey, S., Wurthner, J.U., Parks, W.T., Roberts, A.B. Duckett, C.S. (2001) X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. Journal of Biological Chemistry, 276, 26542 26549. (Pubitemid 37412876)
17. Blanc-Brude, O.P., Mesri, M., Wall, N.R., Plescia, J., Dohi, T. Altieri, D.C. (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clinical Cancer Research, 9, 2683 2692. (Pubitemid 36842114)
18. Boatright, K.M. Salvesen, G.S. (2003) Mechanisms of caspase activation. Current Opinion in Cell Biology, 15, 725 731. (Pubitemid 37492933)
19. Bockbrader, K.M., Tan, M. Sun, Y. (2005) A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene, 24, 7381 7388. (Pubitemid 41622242)
20. Campos, L., Sabido, O., Sebban, C., Charrin, C., Bertheas, M.F., Fiere, D. Guyotat, D. (1996) Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia, 10, 434 438. (Pubitemid 26128781)
21. Carter, B.Z., Kornblau, S.M., Tsao, T., Wang, R.Y., Schober, W.D., Milella, M., Sung, H.G., Reed, J.C. Andreeff, M. (2003a) Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood, 102, 4179 4186. (Pubitemid 37487005)
22. Carter, B.Z., Milella, M., Tsao, T., McQueen, T., Schober, W.D., Hu, W., Dean, N.M., Steelman, L., McCubrey, J.A. Andreeff, M. (2003b) Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia, 17, 2081 2089. (Pubitemid 37428371)
23. Carter, B.Z., Gronda, M., Wang, Z., Welsh, K., Pinilla, C., Andreeff, M., Schober, W.D., Nefzi, A., Pond, G.R., Mawji, I.A., Houghten, R.A., Ostresh, J., Brandwein, J., Minden, M.D., Schuh, A.C., Wells, R.A., Messner, H., Chun, K., Reed, J.C. Schimmer, A.D. (2005) Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood, 105, 4043 4050. (Pubitemid 40656154)
24. Chai, J., Shiozaki, E., Srinivasula, S.M., Wu, Q., Datta, P., Alnemri, E.S. Shi, Y. (2001) Structural basis of caspase-7 inhibition by XIAP. Cell, 104, 769 780. (Pubitemid 32241026)
25. Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., Lavaut, M.N. Allasia, C. (1998) bcl-2 Automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. Journal of Clinical Oncology, 16, 2025 2031. (Pubitemid 28265036)
26. Chauhan, D., Neri, P., Velankar, M., Podar, K., Hideshima, T., Fulciniti, M., Tassone, P., Raje, N., Mitsiades, C., Mitsiades, N., Richardson, P., Zawel, L., Tran, M., Munshi, N. Anderson, K.C. (2007) Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood, 109, 1220 1227. (Pubitemid 46220671)
27. Chen, C.S., Sorensen, P.H., Domer, P.H., Reaman, G.H., Korsmeyer, S.J., Heerema, N.A., Hammond, G.D. Kersey, J.H. (1993) Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood, 81, 2386 2393. (Pubitemid 23127075)
28. Chen, Q., Gong, B., Mahmoud-Ahmed, A.S., Zhou, A., Hsi, E.D., Hussein, M. Almasan, A. (2001) Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood, 98, 2183 2192.
29. Chen, L., Willis, S.N., Wei, A., Smith, B.J., Fletcher, J.I., Hinds, M.G., Colman, P.M., Day, C.L., Adams, J.M. Huang, D.C. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell, 17, 393 403. (Pubitemid 40193310)
30. Chen, S., Dai, Y., Harada, H., Dent, P. Grant, S. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research, 67, 782 791. (Pubitemid 46192219)
31. Choi, J., Hwang, Y.K., Sung, K.W., Lee, S.H., Yoo, K.H., Jung, H.L., Koo, H.H., Kim, H.J., Kang, H.J., Shin, H.Y. Ahn, H.S. (2007) Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood, 109, 471 477. (Pubitemid 46105940)
32. Clodi, K., Wimmer, D., Li, Y., Goodwin, R., Jaeger, U., Mann, G., Gadner, H. Younes, A. (2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. British Journal of Haematology, 111, 580 586. (Pubitemid 32009356)
33. Coustan-Smith, E., Kitanaka, A., Pui, C.H., McNinch, L., Evans, W.E., Raimondi, S.C., Behm, F.G., Arico, M. Campana, D. (1996) Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood, 87, 1140 1146. (Pubitemid 26043542)
34. Dai, Y. Grant, S. (2007) Targeting multiple arms of the apoptotic regulatory machinery. Cancer Research, 67, 2908 2911. (Pubitemid 46724822)
35. Degterev, A., Boyce, M. Yuan, J. (2003) A decade of caspases. Oncogene, 22, 8543 8567. (Pubitemid 38028527)
36. Del Gaizo Moore, V., Brown, J.R., Certo, M., Love, T.M., Novina, C.D. Letai, A. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. Journal of Clinical Investigation, 117, 112 121. (Pubitemid 46048458)
37. Del Gaizo Moore, V., Schlis, K.D., Sallan, S.E., Armstrong, S.A. Letai, A. (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood, 111, 2300 2309.
38. Dohi, T., Okada, K., Xia, F., Wilford, C.E., Samuel, T., Welsh, K., Marusawa, H., Zou, H., Armstrong, R., Matsuzawa, S., Salvesen, G.S., Reed, J.C. Altieri, D.C. (2004) An IAP-IAP complex inhibits apoptosis. Journal of Biological Chemistry, 279, 34087 34090. (Pubitemid 39318028)
39. Du, C., Fang, M., Li, Y., Li, L. Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33 42.
40. Eckelman, B.P., Salvesen, G.S. Scott, F.L. (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Reports, 7, 988 994. (Pubitemid 44480512)
41. Ehrhardt, H., Fulda, S., Schmid, I., Hiscott, J., Debatin, K.M. Jeremias, I. (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene, 22, 3842 3852. (Pubitemid 36819657)
42. Erlacher, M., Michalak, E.M., Kelly, P.N., Labi, V., Niederegger, H., Coultas, L., Adams, J.M., Strasser, A. Villunger, A. (2005) BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood, 106, 4131 4138. (Pubitemid 41775918)
43. Fakler, M., Loder, S., Vogler, M., Schneider, K., Jeremias, I., Debatin, K.M. Fulda, S. 2008) Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood, doi
44. Falschlehner, C., Emmerich, C.H., Gerlach, B. Walczak, H. (2007) TRAIL signalling: decisions between life and death. International Journal of Biochemistry and Cell Biology, 39, 1462 1475. (Pubitemid 47031030)
45. Fulda, S. Debatin, K.M. (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25, 4798 4811. (Pubitemid 44187627)
46. Fulda, S., Wick, W., Weller, M. Debatin, K.M. (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Medicine, 8, 808 815.
47. Gaither, A., Porter, D., Yao, Y., Borawski, J., Yang, G., Donovan, J., Sage, D., Slisz, J., Tran, M., Straub, C., Ramsey, T., Iourgenko, V., Huang, A., Chen, Y., Schlegel, R., Labow, M., Fawell, S., Sellers, W.R. Zawel, L. (2007) A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Research, 67, 11493 11498.
48. Galluzzi, L., Larochette, N., Zamzami, N. Kroemer, G. (2006) Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 25, 4812 4830. (Pubitemid 44192089)
49. Gazitt, Y. (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia, 13, 1817 1824. (Pubitemid 29535266)
50. Georgakis, G.V., Li, Y., Humphreys, R., Andreeff, M., O'Brien, S., Younes, M., Carbone, A., Albert, V. Younes, A. (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. British Journal of Haematology, 130, 501 510. (Pubitemid 43899752)
51. Gronbaek, K., Straten, P.T., Ralfkiaer, E., Ahrenkiel, V., Andersen, M.K., Hansen, N.E., Zeuthen, J., Hou-Jensen, K. Guldberg, P. (1998) Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood, 92, 3018 3024. (Pubitemid 28492305)
52. Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P. Bhalla, K. (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Research, 64, 2580 2589. (Pubitemid 38523916)
53. Hanahan, D. Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57 70. (Pubitemid 30046295)
54. Hengartner, M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770 776.
55. Herbst, R.S., Mendolson, D.S., Ebbinghaus, S., Gordon, M.S., O'Dwyer, P., Liebermann, G., Ing, J., Kurzrock, R., Novotny, W. Eckhardt, G. (2006) A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Journal of Clinical Oncology, 24, 3013.
56. Hofer-Warbinek, R., Schmid, J.A., Stehlik, C., Binder, B.R., Lipp, J. de Martin, R. (2000) Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. Journal of Biological Chemistry, 275, 22064 22068. (Pubitemid 30621784)
57. Hogarth, L.A. Hall, A.G. (1999) Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood, 93, 2671 2678. (Pubitemid 29181200)
58. Holleman, A., den Boer, M.L., de Menezes, R.X., Cheok, M.H., Cheng, C., Kazemier, K.M., Janka-Schaub, G.E., Gobel, U., Graubner, U.B., Evans, W.E. Pieters, R. (2006) The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood, 107, 769 776. (Pubitemid 43076404)
59. Huang, Y., Park, Y.C., Rich, R.L., Segal, D., Myszka, D.G. Wu, H. (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell, 104, 781 790. (Pubitemid 32241027)
60. Humphreys, R.C. Halpern, W. (2008) Trail receptors: targets for cancer therapy. Advances in Experimental Medicine and Biology, 615, 127 158.
61. Hunter, A.M., LaCasse, E.C. Korneluk, R.G. (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis, 12, 1543 1568.
62. Inoue, S., MacFarlane, M., Harper, N., Wheat, L.M., Dyer, M.J. Cohen, G.M. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation, 11 (Suppl. 2 S193 S206.
63. Inoue, S., Mai, A., Dyer, M.J.S. Cohen, G.M. (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Research, 66, 6785 6792. (Pubitemid 44085638)
64. Inoue, S., Walewska, R., Dyer, M.J.S. Cohen, G.M. (2008) Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia, 22, 819 825.
65. Jia, L., Patwari, Y., Kelsey, S.M., Srinivasula, S.M., Agrawal, S.G., Alnemri, E.S. Newland, A.C. (2003) Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene, 22, 1589 1599. (Pubitemid 36408174)
66. Johnstone, R.W., Ruefli, A.A. Lowe, S.W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108, 153 164. (Pubitemid 34161136)
67. Jolivet, J., Dean, E., Ward, T., Denneny, O., Jacob, C., Goodege, P., Dive, C. Ranson, M. (2008) A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. Journal of Clinical Oncology (Meeting Abstracts), 26, 3541.
68. Kang, M.H., Kang, Y.H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M.A., Harned, T.M., Lock, R.B. Reynolds, C.P. (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 110, 2057 2066. (Pubitemid 47443923)
69. Kang, M.H., Wan, Z., Kang, Y.H., Sposto, R. Reynolds, C.P. (2008) Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Journal of the National Cancer Institute, 100, 580 595.
70. Kashkar, H., Haefs, C., Shin, H., Hamilton-Dutoit, S.J., Salvesen, G.S., Kronke, M. Jurgensmeier, J.M. (2003) XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. Journal of Experimental Medicine, 198, 341 347. (Pubitemid 36987859)
71. Kashkar, H., Seeger, J.M., Hombach, A., Deggerich, A., Yazdanpanah, B., Utermohlen, O., Heimlich, G., Abken, H. Kronke, M. (2006) XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood, 108, 3434 3440.
72. Kasof, G.M. Gomes, B.C. (2001) Livin, a novel inhibitor of apoptosis protein family member. Journal of Biological Chemistry, 276, 3238 3246. (Pubitemid 37411617)
73. Kline, M.P., Rajkumar, S.V., Timm, M.M., Kimlinger, T.K., Haug, J.L., Lust, J.A., Greipp, P.R. Kumar, S. (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia, 21, 1549 1560. (Pubitemid 46965297)
74. Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P.P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., Verhaegen, M., Soengas, M., Ruvolo, V.R., McQueen, T., Schober, W.D., Watt, J.C., Jiffar, T., Ling, X., Marini, F.C., Harris, D., Dietrich, M., Estrov, Z., McCubrey, J., May, W.S., Reed, J.C. Andreeff, M. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 10, 375 388.
75. Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I. Andreeff, M. (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Research, 68, 3413 3420.
76. Kroemer, G., Galluzzi, L. Brenner, C. (2007) Mitochondrial membrane permeabilization in cell death. Physiological Reviews, 87, 99 163. (Pubitemid 46209992)
77. Kuroda, J., Kimura, S., Andreeff, M., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., Tanaka, R., Murotani, Y., Matsumoto, Y., Tanaka, H., Strasser, A., Taniwaki, M. Maekawa, T. (2008) ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. British Journal of Haematology, 140, 181 190. (Pubitemid 350265045)
78. LaCasse, E.C., Kandimalla, E.R., Winocour, P., Sullivan, T., Agrawal, S., Gillard, J.W. Durkin, J. (2005) Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Annals of the New York Academy of Sciences, 1058, 215 234.
79. LaCasse, E.C., Cherton-Horvat, G.G., Hewitt, K.E., Jerome, L.J., Morris, S.J., Kandimalla, E.R., Yu, D., Wang, H., Wang, W., Zhang, R., Agrawal, S., Gillard, J.W. Durkin, J.P. (2006a) Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clinical Cancer Research, 12, 5231 5241. (Pubitemid 44453353)
80. LaCasse, E., Morris, S., Ward, T., Cumings, J., Robson, L., Di Tullio, K., Methot, D., Jerome, L., Winocour, P., Gillard, J.W., Jolivet, J., Jodrell, D., Ranson, M. Durkin, J. (2006b) AEG 35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolatedd from pre-clinical models and from patients. American Association for Cancer Research Annual Meeting, 66, 4862.
81. Lavrik, I., Golks, A. Krammer, P.H. (2005) Death receptor signaling. Journal of Cell Science, 118, 265 267. (Pubitemid 40277339)
82. LeBlanc, H.N. Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation, 10, 66 75. (Pubitemid 36511833)
83. Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S. Korsmeyer, S.J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183 192. (Pubitemid 41043974)
84. Levkau, B., Garton, K.J., Ferri, N., Kloke, K., Nofer, J.R., Baba, H.A., Raines, E.W. Breithardt, G. (2001) xIAP induces cell-cycle arrest and activates nuclear factor-kappaB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circulation Research, 88, 282 290. (Pubitemid 32173751)
85. Lewis, J., Burstein, E., Reffey, S.B., Bratton, S.B., Roberts, A.B. Duckett, C.S. (2004) Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. Journal of Biological Chemistry, 279, 9023 9029. (Pubitemid 38295965)
86. Li, L., Thomas, R.M., Suzuki, H., De Brabander, J.K., Wang, X. Harran, P.G. (2004) A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science, 305, 1471 1474. (Pubitemid 39167668)
87. Lima, R.T., Martins, L.M., Guimaraes, J.E., Sambade, C. Vasconcelos, M.H. (2006) Chemosensitization effects of XIAP downregulation in K562 leukemia cells. Journal of Chemotherapy, 18, 98 102.
88. Lin, X., Morgan-Lappe, S., Huang, X., Li, L., Zakula, D.M., Vernetti, L.A., Fesik, S.W. Shen, Y. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene, 26, 3972 3979. (Pubitemid 46884293)
89. Liu, Q., El-Deiry, W.S. Gazitt, Y. (2001) Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Experimental Hematology, 29, 962 970. (Pubitemid 32725794)
90. Lock, R., Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J. Smith, M.A. (2008) Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50, 1181 1189.
91. Lu, M., Lin, S.-C., Huang, Y., Kang, Y.J., Rich, R., Lo, Y.-C., Myszka, D., Han, J. Wu, H. (2007) XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Molecular Cell, 26, 689 702. (Pubitemid 46856243)
92. Mason, K.D., Carpinelli, M.R., Fletcher, J.I., Collinge, J.E., Hilton, A.A., Ellis, S., Kelly, P.N., Ekert, P.G., Metcalf, D., Roberts, A.W., Huang, D.C.S. Kile, B.T. (2007) Programmed anuclear cell death delimits platelet life span. Cell, 128, 1173 1186. (Pubitemid 46427871)
93. Mehta, P.A., Gerbing, R.B., Alonzo, T.A., Elliott, J.S., Zamzow, T.A., Combs, M., Stover, E., Ross, J.A., Perentesis, J.P., Meschinchi, S., Lange, B.J. Davies, S.M. (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clinical Cancer Research, 14, 7896 7899.
94. Melo, J.V. Deininger, M.W.N. (2004) Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematology - Oncology Clinics of North America, 18, 545 568. (Pubitemid 38969131)
95. Meng, X.W., Lee, S.-H., Dai, H., Loegering, D., Yu, C., Flatten, K., Schneider, P., Dai, N.T., Kumar, S.K., Smith, B.D., Karp, J.E., Adjei, A.A. Kaufmann, S.H. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Journal of Biological Chemistry, 282, 29831 29846. (Pubitemid 350035287)
96. Mitsiades, C.S., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T. Anderson, K.C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood, 98, 795 804.
97. Nachmias, B., Ashhab, Y., Bucholtz, V., Drize, O., Kadouri, L., Lotem, M., Peretz, T., Mandelboim, O. Ben-Yehuda, D. (2003) Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Research, 63, 6340 6349. (Pubitemid 37255182)
98. Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M. Sakai, T. (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 23, 6261 6271. (Pubitemid 39215296)
99. Narayan, S., Chandra, J., Sharma, M., Naithani, R. Sharma, S. (2007) Expression of apoptosis regulators Bcl-2 and Bax in childhood acute lymphoblastic leukemia. Hematology, 12, 39 43. (Pubitemid 46394868)
100. Nguyen, M., Marcellus, R.C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S.R., Goulet, D., Viallet, J., Belec, L., Billot, X., Acoca, S., Purisima, E., Wiegmans, A., Cluse, L., Johnstone, R.W., Beauparlant, P. Shore, G.C. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104, 19512 19517.
101. O'Brien, S., Moore, J.O., Boyd, T.E., Larratt, L.M., Skotnicki, A., Koziner, B., Chanan-Khan, A.A., Seymour, J.F., Bociek, R.G., Pavletic, S. Rai, K.R. (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 1114 1120. (Pubitemid 46596764)
102. O'Neil, J. Look, A.T. (2007) Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene, 26, 6838 6849. (Pubitemid 47585107)
103. Okada, H. Mak, T.W. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Reviews Cancer, 4, 592 603. (Pubitemid 39025054)
104. Olsson, A., Diaz, T., Aguilar-Santelises, M., Osterborg, A., Celsing, F., Jondal, M. Osorio, L.M. (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia, 15, 1868 1877. (Pubitemid 33114993)
105. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., Joseph, M.K., Kitada, S., Korsmeyer, S.J., Kunzer, A.R., Letai, A., Li, C., Mitten, M.J., Nettesheim, D.G., Ng, S., Nimmer, P.M., O'Connor, J.M., Oleksijew, A., Petros, A.M., Reed, J.C., Shen, W., Tahir, S.K., Thompson, C.B., Tomaselli, K.J., Wang, B., Wendt, M.D., Zhang, H., Fesik, S.W. Rosenberg, S.H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677 681. (Pubitemid 40825512)
106. Oost, T.K., Sun, C., Armstrong, R.C., Al-Assaad, A.S., Betz, S.F., Deckwerth, T.L., Ding, H., Elmore, S.W., Meadows, R.P., Olejniczak, E.T., Oleksijew, A., Oltersdorf, T., Rosenberg, S.H., Shoemaker, A.R., Tomaselli, K.J., Zou, H. Fesik, S.W. (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. Journal of Medicinal Chemistry, 47, 4417 4426. (Pubitemid 39096830)
107. Patnaik, A., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N., Howard, T., Ulltich, S., Tolcher, A. Sikic, B. (2006) HGS-ETR2 A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. Journal of Clinical Oncology, 24, 3012.
108. Perez-Galan, P., Roue, G., Lopez-Guerra, M., Nguyen, M., Villamor, N., Montserrat, E., Shore, G.C., Campo, E. Colomer, D. (2008) BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 22, 1712 1720.
109. Petersen, S.L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., Harran, P. Wang, X. (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell, 12, 445 456. (Pubitemid 350064365)
110. Planey, S.L., Abrams, M.T., Robertson, N.M. Litwack, G. (2003) Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Research, 63, 172 178. (Pubitemid 36070437)
111. Plasilova, M., Zivny, J., Jelinek, J., Neuwirtova, R., Cermak, J., Necas, E., Andera, L. Stopka, T. (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia, 16, 67 73. (Pubitemid 34105601)
112. Prokop, A., Wieder, T., Sturm, I., Essmann, F., Seeger, K., Wuchter, C., Ludwig, W.D., Henze, G., Dorken, B. Daniel, P.T. (2000) Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia, 14, 1606 1613.
113. Pui, C.H., Behm, F.G., Downing, J.R., Hancock, M.L., Shurtleff, S.A., Ribeiro, R.C., Head, D.R., Mahmoud, H.H., Sandlund, J.T. Furman, W.L. (1994) 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. Journal of Clinical Oncology, 12, 909 915. (Pubitemid 24983452)
114. Reed, J.C. (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood, 111, 3322 3330.
115. Reed, J.C. Pellecchia, M. (2005) Apoptosis-based therapies for hematologic malignancies. Blood, 106, 408 418. (Pubitemid 40981231)
116. Riedl, S.J. Salvesen, G.S. (2007) The apoptosome: signalling platform of cell death. Nature Reviews Molecular Cell Biology, 8, 405 413. (Pubitemid 46643237)
117. Riedl, S.J., Renatus, M., Schwarzenbacher, R., Zhou, Q., Sun, C., Fesik, S.W., Liddington, R.C. Salvesen, G.S. (2001) Structural basis for the inhibition of caspase-3 by XIAP. Cell, 104, 791 800. (Pubitemid 32241028)
118. Rosato, R.R., Almenara, J.A., Coe, S. Grant, S. (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Research, 67, 9490 9500. (Pubitemid 47535939)
119. Rowley, J.D. (2008) Chromosomal translocations: revisited yet again. Blood, 112, 2183 2189.
120. Saleh, M.N., Percent, I., Wood, T.E., Posey, J., Shah, J., Carlisle, R., Wojtowicz-Praga, S. Forero-Torres, A. (2008) A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. Journal of Clinical Oncology (Meeting Abstracts), 26, 3537.
121. Salomons, G.S., Smets, L.A., Verwijs-Janssen, M., Hart, A.A., Haarman, E.G., Kaspers, G.J., Wering, E.V., Der Does-Van Den Berg, A.V. Kamps, W.A. (1999) Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia, 13, 1574 1580. (Pubitemid 29465620)
122. Salvesen, G.S. Duckett, C.S. (2002) IAP proteins: blocking the road to death's door. Nature Reviews Molecular Cell Biology, 3, 401 410. (Pubitemid 34685698)
123. Sanna, M.G., da Silva Correia, J., Ducrey, O., Lee, J., Nomoto, K., Schrantz, N., Deveraux, Q.L. Ulevitch, R.J. (2002) IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Molecular and Cellular Biology, 22, 1754 1766. (Pubitemid 34174993)
124. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H. Peter, M.E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal, 17, 1675 1687. (Pubitemid 28119121)
125. Schimmer, A.D. (2008) Apoptosis in leukemia: from molecular pathways to targeted therapies. Bailliere's Best Practice in Clinical Haematology, 21, 5 11.
126. Schimmer, A.D., Munk-Pedersen, I., Minden, M.D. Reed, J.C. (2003) Bcl-2 and apoptosis in chronic lymphocytic leukemia. Current Treatment Options in Oncology, 4, 211 218.
127. Schimmer, A.D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau,
128. Schmidt, S., Rainer, J., Riml, S., Ploner, C., Jesacher, S., Achmuller, C., Presul, E., Skvortsov, S., Crazzolara, R., Fiegl, M., Raivio, T., Janne, O.A., Geley, S., Meister, B. Kofler, R. (2006) Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood, 107, 2061 2069. (Pubitemid 43292367)
129. Shiozaki, E.N. Shi, Y. (2004) Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends in Biochemical Sciences, 29, 486 494. (Pubitemid 39158872)
130. Shiozaki, E.N., Chai, J., Rigotti, D.J., Riedl, S.J., Li, P., Srinivasula, S.M., Alnemri, E.S., Fairman, R. Shi, Y. (2003) Mechanism of XIAP-mediated inhibition of caspase-9. Molecular Cell, 11, 519 527. (Pubitemid 36293842)
131. Sibley, K., Rollinson, S., Allan, J.M., Smith, A.G., Law, G.R., Roddam, P.L., Skibola, C.F., Smith, M.T. Morgan, G.J. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Research, 63, 4327 4330. (Pubitemid 36950998)
132. Snell, V., Clodi, K., Zhao, S., Goodwin, R., Thomas, E.K., Morris, S.W., Kadin, M.E., Cabanillas, F., Andreeff, M. Younes, A. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. British Journal of Haematology, 99, 618 624. (Pubitemid 27519865)
133. Song, Z., Yao, X. Wu, M. (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. Journal of Biological Chemistry, 278, 23130 23140. (Pubitemid 36830379)
134. Srinivasula, S.M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., Lee, R.A., Robbins, P.D., Fernandes-Alnemri, T., Shi, Y. Alnemri, E.S. (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature, 410, 112 116. (Pubitemid 32225846)
135. Sun, H., Nikolovska-Coleska, Z., Yang, C.Y., Xu, L., Liu, M., Tomita, Y., Pan, H., Yoshioka, Y., Krajewski, K., Roller, P.P. Wang, S. (2004a) Structure-based design of potent, conformationally constrained Smac mimetics. Journal of the American Chemical Society, 126, 16686 16687. (Pubitemid 40069464)
136. Sun, H., Nikolovska-Coleska, Z., Yang, C.Y., Xu, L., Tomita, Y., Krajewski, K., Roller, P.P. Wang, S. (2004b) Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. Journal of Medicinal Chemistry, 47, 4147 4150. (Pubitemid 39045419)
137. Sun, H., Nikolovska-Coleska, Z., Lu, J., Qiu, S., Yang, C.Y., Gao, W., Meagher, J., Stuckey, J. Wang, S. (2006) Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. Journal of Medicinal Chemistry, 49, 7916 7920. (Pubitemid 46033683)
138. Szegedi, I., Katona, K., Horvath, A., Molnar, A., Aradi, J. Kiss, C. (2008) Bcl-2 antisense oligonucleotide inhibits the proliferation of childhood leukemia/lymphoma cells of the B-cell lineage. Pathology Oncology Research, 14, 275 279.
139. Tahir, S.K., Yang, X., Anderson, M.G., Morgan-Lappe, S.E., Sarthy, A.V., Chen, J., Warner, R.B., Ng, S.-C., Fesik, S.W., Elmore, S.W., Rosenberg, S.H. Tse, C. (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Research, 67, 1176 1183. (Pubitemid 46270776)
140. Tamm, I., Richter, S., Oltersdorf, D., Creutzig, U., Harbott, J., Scholz, F., Karawajew, L., Ludwig, W.-D. Wuchter, C. (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clinical Cancer Research, 10, 3737 3744. (Pubitemid 38697607)
141. Taylor, K., Micha, D., Ranson, M. Dive, C. (2006) Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opinion on Investigational Drugs, 15, 669 690. (Pubitemid 43919302)
142. Tolcher, A.W. (2005) Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clinical Advances in Hematology and Oncology, 3, 635 642. (Pubitemid 41403805)
143. Tolcher, A.W., Mita, M., Meropol, N.J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N.L., Halpern, W., Corey, A. Cohen, R.B. (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. Journal of Clinical Oncology, 25, 1390 1395. (Pubitemid 46706887)
144. Troeger, A., Siepermann, M., Escherich, G., Meisel, R., Willers, R., Gudowius, S., Moritz, T., Laws, H.J., Hanenberg, H., Goebel, U., Janka-Schaub, G.E., Mahotka, C. Dilloo, D. (2007) Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica, 92, 1043 1050. (Pubitemid 350144210)
145. Tröger, A., Siepermann, M., Mahotka, C., Wethkamp, N., Bulle, H., Laws, H.J., Escherich, G., Janka-Schaub, G., Gobel, U. Dilloo, D. (2007) Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klinische Padiatrie, 219, 127 133. (Pubitemid 46983774)
146. Tsapis, M., Lieb, M., Manzo, F., Shankaranarayanan, P., Herbrecht, R., Lutz, P. Gronemeyer, H. (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. International Journal of Biochemistry and Cell Biology, 39, 1500 1509. (Pubitemid 47031039)
147. Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S., Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., Roberts, L., Tahir, S.K., Xiao, Y., Yang, X., Zhang, H., Fesik, S., Rosenberg, S.H. Elmore, S.W. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research, 68, 3421 3428.
148. Van Delft, M.F., Wei, A.H., Mason, K.D., Vandenberg, C.J., Chen, L., Czabotar, P.E., Willis, S.N., Scott, C.L., Day, C.L., Cory, S., Adams, J.M., Roberts, A.W. Huang, D.C.S. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 10, 389 399.
149. Varfolomeev, E., Blankenship, J.W., Wayson, S.M., Fedorova, A.V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J.N., Elliott, L.O., Wallweber, H.J., Flygare, J.A., Fairbrother, W.J., Deshayes, K., Dixit, V.M. Vucic, D. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell, 131, 669 681. (Pubitemid 350087204)
150. Vaux, D.L. Silke, J. (2005) IAPs, RINGs and ubiquitylation. Nature Reviews Molecular Cell Biology, 6, 287 297. (Pubitemid 40516895)
151. Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E., Moritz, R.L., Simpson, R.J. Vaux, D.L. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 102, 43 53.
152. Vince, J.E., Wong, W.W., Khan, N., Feltham, R., Chau, D., Ahmed, A.U., Benetatos, C.A., Chunduru, S.K., Condon, S.M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B.A., Koentgen, F., Vaux, D.L. Silke, J. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell, 131, 682 693. (Pubitemid 350103599)
153. Vogler, M., Dinsdale, D., Sun, X.M., Young, K.W., Butterworth, M., Nicotera, P., Dyer, M.J.S. Cohen, G.M. (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death and Differentiation, 15, 820 830.
154. Vucic, D., Stennicke, H.R., Pisabarro, M.T., Salvesen, G.S. Dixit, V.M. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Current Biology, 10, 1359 1366.
155. Vucic, D., Deshayes, K., Ackerly, H., Pisabarro, M.T., Kadkhodayan, S., Fairbrother, W.J. Dixit, V.M. (2002) SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). Journal of Biological Chemistry, 277, 12275 12279.
156. Vucic, D., Franklin, M.C., Wallweber, H.J.A., Das, K., Eckelman, B.P., Shin, H., Elliott, L.O., Kadkhodayan, S., Deshayes, K., Salvesen, G.S. Fairbrother, W.J. (2005) Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochemical Journal, 385, 11 20.
157. Wagner, M., Schmelz, K., Wuchter, C., Ludwig, W.D., Dorken, B. Tamm, I. (2006) In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. International Journal of Cancer, 119, 1291 1297. (Pubitemid 44258802)
158. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C. Lynch, D.H. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine, 5, 157 163. (Pubitemid 29068521)
159. Wang, Z., Malone, M.H., He, H., McColl, K.S. Distelhorst, C.W. (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. Journal of Biological Chemistry, 278, 23861 23867. (Pubitemid 36830212)
160. Wang, Z., Cuddy, M., Samuel, T., Welsh, K., Schimmer, A., Hanaii, F., Houghten, R., Pinilla, C. Reed, J.C. (2004) Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. Journal of Biological Chemistry, 279, 48168 48176. (Pubitemid 39540972)
161. Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F. Cotter, F.E. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 18, 1812 1823. (Pubitemid 30261918)
162. Webb, A., Cunningham, D., Cotter, F., Clarke, P.A., di Stefano, F., Ross, P., Corbo, M. Dziewanowska, Z. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349, 1137 1141. (Pubitemid 27168548)
163. Webb, M.S., Miller, A.L., Johnson, B.H., Fofanov, Y., Li, T., Wood, T.G. Thompson, E.B. (2003) Gene networks in glucocorticoid-evoked apoptosis of leukemic cells. Journal of Steroid Biochemistry and Molecular Biology, 85, 183 193. (Pubitemid 37020887)
164. Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R.W., Opferman, J.T., Sallan, S.E., den Boer, M.L., Pieters, R., Golub, T.R. Armstrong, S.A. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 10, 331 342. (Pubitemid 44512194)
165. Weisberg, E., Kung, A.L., Wright, R.D., Moreno, D., Catley, L., Ray, A., Zawel, L., Tran, M., Cools, J., Gilliland, G., Mitsiades, C., McMillin, D.W., Jiang, J., Hall-Meyers, E. Griffin, J.D. (2007) Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics, 6, 1951 1961. (Pubitemid 47052485)
166. Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E. Bhalla, K. (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood, 96, 3900 3906.
167. Willis, S.N., Fletcher, J.I., Kaufmann, T., van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.M., Adams, J.M. Huang, D.C. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science, 315, 856 859. (Pubitemid 46264314)
168. Wilson, W.H., Czuczman, M.S., LaCasce, A.S., Gerecitano, J.F., Leonard, J.P., Dunleavy, K., Krivoshik, A.P., Xiong, H., Chiu, Y. O'Connor, O.A. (2008) A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Journal of Clinical Oncology (Meeting Abstracts), 26, 8511.
169. Wuchter, C., Karawajew, L., Ruppert, V., Schrappe, M., Harbott, J., Ratei, R., Dorken, B. Ludwig, W.D. (2000) Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 110, 154 160. (Pubitemid 30625603)
170. Yang, L., Cao, Z., Yan, H. Wood, W.C. (2003) Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Research, 63, 6815 6824. (Pubitemid 37322964)
171. Younes, A., Vose, J.M. Zelenetz, A.D. (2005) Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (ETR1-HM01). Blood Abstract, 106, 489.
172. Zhang, H., Nimmer, P.M., Tahir, S.K., Chen, J., Fryer, R.M., Hahn, K.R., Iciek, L.A., Morgan, S.J., Nasarre, M.C., Nelson, R., Preusser, L.C., Reinhart, G.A., Smith, M.L., Rosenberg, S.H., Elmore, S.W. Tse, C. (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death and Differentiation, 14, 943 951. (Pubitemid 46655455)
173. Zobel, K., Wang, L., Varfolomeev, E., Franklin, M.C., Elliott, L.O., Wallweber, H.J., Okawa, D.C., Flygare, J.A., Vucic, D., Fairbrother, W.J. Deshayes, K. (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chemical Biology, 1, 525 533.